Cardiac Biomarkers Market Size, Share & Trends Report

Cardiac Biomarkers Market (2025 - 2030) Size, Share & Trends Analysis Report By Type (Troponin, CK-MB, Myoglobin, BNP and NT-proBNP, Others), By Application, By End Use, By Region, And Segment Forecasts

Market Segmentation

Cardiac Biomarkers Type Outlook (Revenue in USD Million, 2018 - 2030)
- Troponin
- CK-MB
- Myoglobin
- BNP AND NT-PROBNP
- Others
Cardiac Biomarkers Application Outlook (Revenue in USD Million, 2018 - 2030)
- Acute Coronary Syndrome
- Myocardial Infarction
- Congestive Heart Failure
- Others
Cardiac Biomarkers End Use Outlook (Revenue in USD Million; 2018 - 2030)
- Laboratory Testing
- Point of Care Testing
Cardiac Biomarkers Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
  - North America Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Troponin
    - CK-MB
    - Myoglobin
    - BNP AND NT-PROBNP
    - Others
  - North America Application Outlook (Revenue in USD Million, 2018 - 2030)
    - Acute Coronary Syndrome
    - Myocardial Infarction
    - Congestive Heart Failure
    - Others
  - North America Application Outlook (Revenue in USD Million, 2018 - 2030)
    - Laboratory Testing
    - Point of Care Testing
  - U.S.
    - U.S. Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Troponin
      - CK-MB
      - Myoglobin
      - BNP AND NT-PROBNP
      - Others
    - U.S. Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Acute Coronary Syndrome
      - Myocardial Infarction
      - Congestive Heart Failure
      - Others
    - U.S. End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Laboratory Testing
      - Point of Care Testing
  - Canada
    - Canada Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Troponin
      - CK-MB
      - Myoglobin
      - BNP AND NT-PROBNP
      - Others
    - Canada Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Acute Coronary Syndrome
      - Myocardial Infarction
      - Congestive Heart Failure
      - Others
    - Canada End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Laboratory Testing
      - Point of Care Testing
  - Mexico
    - Mexico Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Troponin
      - CK-MB
      - Myoglobin
      - BNP AND NT-PROBNP
      - Others
    - Mexico Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Acute Coronary Syndrome
      - Myocardial Infarction
      - Congestive Heart Failure
      - Others
    - Mexico End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Laboratory Testing
      - Point of Care Testing
- Europe
  - Europe Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Troponin
    - CK-MB
    - Myoglobin
    - BNP AND NT-PROBNP
    - Others
  - Europe Application Outlook (Revenue in USD Million, 2018 - 2030)
    - Acute Coronary Syndrome
    - Myocardial Infarction
    - Congestive Heart Failure
    - Others
  - Europe End Use Outlook (Revenue in USD Million, 2018 - 2030)
    - Laboratory Testing
    - Point of Care Testing
  - Germany
    - Germany Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Troponin
      - CK-MB
      - Myoglobin
      - BNP AND NT-PROBNP
      - Others
    - Germany Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Acute Coronary Syndrome
      - Myocardial Infarction
      - Congestive Heart Failure
      - Others
    - Germany End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Laboratory Testing
      - Point of Care Testing
  - UK
    - UK Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Troponin
      - CK-MB
      - Myoglobin
      - BNP AND NT-PROBNP
      - Others
    - UK Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Acute Coronary Syndrome
      - Myocardial Infarction
      - Congestive Heart Failure
      - Others
    - UK End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Laboratory Testing
      - Point of Care Testing
  - France
    - France Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Troponin
      - CK-MB
      - Myoglobin
      - BNP AND NT-PROBNP
      - Others
    - France Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Acute Coronary Syndrome
      - Myocardial Infarction
      - Congestive Heart Failure
      - Others
    - France End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Laboratory Testing
      - Point of Care Testing
  - Italy
    - Italy Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Troponin
      - CK-MB
      - Myoglobin
      - BNP AND NT-PROBNP
      - Others
    - Italy Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Acute Coronary Syndrome
      - Myocardial Infarction
      - Congestive Heart Failure
      - Others
    - Italy End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Laboratory Testing
      - Point of Care Testing
  - Spain
    - Spain Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Troponin
      - CK-MB
      - Myoglobin
      - BNP AND NT-PROBNP
      - Others
    - Spain Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Acute Coronary Syndrome
      - Myocardial Infarction
      - Congestive Heart Failure
      - Others
    - Spain End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Laboratory Testing
      - Point of Care Testing
  - Denmark
    - Denmark Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Troponin
      - CK-MB
      - Myoglobin
      - BNP AND NT-PROBNP
      - Others
    - Denmark Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Acute Coronary Syndrome
      - Myocardial Infarction
      - Congestive Heart Failure
      - Others
    - Denmark End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Laboratory Testing
      - Point of Care Testing
  - Sweden
    - Sweden Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Troponin
      - CK-MB
      - Myoglobin
      - BNP AND NT-PROBNP
      - Others
    - Sweden Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Acute Coronary Syndrome
      - Myocardial Infarction
      - Congestive Heart Failure
      - Others
    - Sweden End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Laboratory Testing
      - Point of Care Testing
  - Norway
    - Norway Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Troponin
      - CK-MB
      - Myoglobin
      - BNP AND NT-PROBNP
      - Others
    - Norway Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Acute Coronary Syndrome
      - Myocardial Infarction
      - Congestive Heart Failure
      - Others
    - Norway End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Laboratory Testing
      - Point of Care Testing
- Asia Pacific
  - Asia Pacific Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Troponin
    - CK-MB
    - Myoglobin
    - BNP AND NT-PROBNP
    - Others
  - Asia Pacific Application Outlook (Revenue in USD Million, 2018 - 2030)
    - Acute Coronary Syndrome
    - Myocardial Infarction
    - Congestive Heart Failure
    - Others
  - Asia Pacific End Use Outlook (Revenue in USD Million, 2018 - 2030)
    - Laboratory Testing
    - Point of Care Testing
  - China
    - China Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Troponin
      - CK-MB
      - Myoglobin
      - BNP AND NT-PROBNP
      - Others
    - China End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Acute Coronary Syndrome
      - Myocardial Infarction
      - Congestive Heart Failure
      - Others
    - China Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Laboratory Testing
      - Point of Care Testing
  - Japan
    - Japan Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Troponin
      - CK-MB
      - Myoglobin
      - BNP AND NT-PROBNP
      - Others
    - Japan Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Acute Coronary Syndrome
      - Myocardial Infarction
      - Congestive Heart Failure
      - Others
    - Japan End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Laboratory Testing
      - Point of Care Testing
    - India Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Troponin
      - CK-MB
      - Myoglobin
      - BNP AND NT-PROBNP
      - Others
    - India End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Acute Coronary Syndrome
      - Myocardial Infarction
      - Congestive Heart Failure
      - Others
    - India Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Laboratory Testing
      - Point of Care Testing
  - Thailand
    - Thailand Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Troponin
      - CK-MB
      - Myoglobin
      - BNP AND NT-PROBNP
      - Others
    - Thailand Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Acute Coronary Syndrome
      - Myocardial Infarction
      - Congestive Heart Failure
      - Others
    - Thailand End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Laboratory Testing
      - Point of Care Testing
  - South Korea
    - South Korea Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Troponin
      - CK-MB
      - Myoglobin
      - BNP AND NT-PROBNP
      - Others
    - South Korea Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Acute Coronary Syndrome
      - Myocardial Infarction
      - Congestive Heart Failure
      - Others
    - South Korea End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Laboratory Testing
      - Point of Care Testing
  - Australia
    - Australia Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Troponin
      - CK-MB
      - Myoglobin
      - BNP AND NT-PROBNP
      - Others
    - Australia Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Acute Coronary Syndrome
      - Myocardial Infarction
      - Congestive Heart Failure
      - Others
    - Australia End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Laboratory Testing
      - Point of Care Testing
- Latin America
  - Latin America Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Troponin
    - CK-MB
    - Myoglobin
    - BNP AND NT-PROBNP
    - Others
  - Latin America Application Outlook (Revenue in USD Million, 2018 - 2030)
    - Acute Coronary Syndrome
    - Myocardial Infarction
    - Congestive Heart Failure
    - Others
  - Latin America End Use Outlook (Revenue in USD Million, 2018 - 2030)
    - Laboratory Testing
    - Point of Care Testing
  - Brazil
    - Brazil Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Troponin
      - CK-MB
      - Myoglobin
      - BNP AND NT-PROBNP
      - Others
    - Brazil Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Acute Coronary Syndrome
      - Myocardial Infarction
      - Congestive Heart Failure
      - Others
    - Brazil End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Laboratory Testing
      - Point of Care Testing
  - Argentina
    - Argentina Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Troponin
      - CK-MB
      - Myoglobin
      - BNP AND NT-PROBNP
      - Others
    - Argentina Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Acute Coronary Syndrome
      - Myocardial Infarction
      - Congestive Heart Failure
      - Others
    - Argentina End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Laboratory Testing
      - Point of Care Testing
- Middle East and Africa
  - Middle East and Africa Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Troponin
    - CK-MB
    - Myoglobin
    - BNP AND NT-PROBNP
    - Others
  - Middle East and Africa Application Outlook (Revenue in USD Million, 2018 - 2030)
    - Acute Coronary Syndrome
    - Myocardial Infarction
    - Congestive Heart Failure
    - Others
  - Middle East and Africa End Use Outlook (Revenue in USD Million, 2018 - 2030)
    - Laboratory Testing
    - Point of Care Testing
  - South Africa
    - South Africa Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Troponin
      - CK-MB
      - Myoglobin
      - BNP AND NT-PROBNP
      - Others
    - South Africa Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Acute Coronary Syndrome
      - Myocardial Infarction
      - Congestive Heart Failure
      - Others
    - South Africa End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Laboratory Testing
      - Point of Care Testing
  - Saudi Arabia
    - Saudi Arabia Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Troponin
      - CK-MB
      - Myoglobin
      - BNP AND NT-PROBNP
      - Others
    - Saudi Arabia Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Acute Coronary Syndrome
      - Myocardial Infarction
      - Congestive Heart Failure
      - Others
    - Saudi Arabia End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Laboratory Testing
      - Point of Care Testing
  - UAE
    - UAE Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Troponin
      - CK-MB
      - Myoglobin
      - BNP AND NT-PROBNP
      - Others
    - UAE Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Acute Coronary Syndrome
      - Myocardial Infarction
      - Congestive Heart Failure
      - Others
    - UAE End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Laboratory Testing
      - Point of Care Testing
  - Kuwait
    - Kuwait Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Troponin
      - CK-MB
      - Myoglobin
      - BNP AND NT-PROBNP
      - Others
    - Kuwait Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Acute Coronary Syndrome
      - Myocardial Infarction
      - Congestive Heart Failure
      - Others
    - Kuwait End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Laboratory Testing
      - Point of Care Testing

Report content

Qualitative Analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments